Breast Cancer
25 videos · last 6 months shuffled daily, then older videos newest first
▶
20:55 SERENA-6 and the FDA Approval of Camizestrant
Dr. Erica Mayer, a breast medical oncologist at Dana-Farber Cancer Institute, discusses the design and findings of the SERENA-6 trial behind the FDA approval of camizestrant in hormone receptor-positive metastatic breast cancer, for Oncology Brothers.
▶
19:54 Breast Cancer Trials at ASCO 2026: BWEL, lidERA and More
Komen Scholars Jennifer Ligibel, MD, of Dana-Farber and Mariana Chavez MacGregor, MD, of MD Anderson, with Elizabeth McDonald, MD, discuss ASCO 2026 breast cancer trials including BWEL, OPTIMA, lidERA, persevERA and evERA, for Susan G. Komen.
▶
1:55 KEYNOTE-522 Update for Triple-Negative Breast Cancer
Dr. Bill Gradishar explains the seven-year KEYNOTE-522 update in triple-negative breast cancer, which showed continued event-free and overall survival benefits with longer follow-up, for Yerbba.
▶
35:11 Cancer Unfiltered Ep. 3: New FDA Approvals, Practice-Changing Trials & What's Next in Breast Cancer
Dr. Komal Jhaveri and Dr. Neil Iyengar discuss recent FDA approvals, recent clinical trials, and emerging treatment strategies across HR-positive, HER2-positive and triple-negative breast cancer.
▶
2:17 SENOMAC Trial: Less Lymph Node Surgery in Breast Cancer
Dr. Bill Gradishar explains the SENOMAC trial, which looked at whether breast cancer patients with one or two positive axillary lymph nodes could avoid a full axillary dissection, for Yerbba.
▶
9:53 ASCO 2026: Breast Cancer Weight Loss (BWEL) Trial
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute discuss new research from the Breast Cancer Weight Loss (BWEL) trial, along with lifestyle, diet and GLP-1 agonists.
▶
1:59 ASCO 2026: Giredestrant Trials lidERA, persevERA, evERA
Mariana Chavez MacGregor, M.D., of MD Anderson Cancer Center discusses the lidERA, persevERA and evERA trials of giredestrant presented at ASCO 2026, for Susan G. Komen.
▶
10:02 Phase 3 Globo H Vaccine Trial in Triple-Negative Breast Cancer
Dr Hope Rugo tells ecancer about a phase 3 trial of adagloxad simolenin, a globo H-targeting cancer vaccine, with the adjuvant OBI-821 in high-risk early triple-negative breast cancer, stopped early for futility with no survival difference.
▶
39:29 ASCO 2026: Highlights and Analysis
Associate Professor Bishal Gyawali talks to ecancer about ASCO 2026 presentations across GI, pancreatic, lung, breast and prostate cancer, including daraxonrasib in metastatic pancreatic adenocarcinoma.
▶
5:20 Guardant360 CDx Approved as Camizestrant Companion Test
Guardant Health chairman and co-CEO Helmy Eltoukhy discusses on CNBC the FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer.
▶
4:16 Helmy Eltoukhy on CNN’s The Situation Room: A New Era in Blood-Based Cancer Monitoring
Guardant Health co-CEO Helmy Eltoukhy tells CNN how a blood test that monitors tumor mutations received FDA approval to help inform treatment in some advanced breast cancer patients.
▶
1:42 ASCO 2026: VIKTORIA-1 and PANKU-Breast02 Trials
Kelsey Hampton, Ph.D., Director of Mission Communications and Education at Susan G. Komen, discusses the VIKTORIA-1 and PANKU-Breast02 trials presented at ASCO 2026.
▶
1:56 VIKTORIA-1: Gedatolisib in ER+ Metastatic Breast Cancer
Dr. Bill Gradishar explains the VIKTORIA-1 trial results for gedatolisib in ER-positive metastatic breast cancer, including improvements in progression-free survival, for Yerbba.
▶
58:46 [LTRN Webinar] Inside the Data - LP-184 Phase 1a Results and Future Trials with Dr. Igor Astsaturov
Lantern Pharma and Dr. Igor Astsaturov of Fox Chase Cancer Center review Phase 1a results for LP-184, a synthetic lethal candidate for advanced solid tumours, and plans for further trials.
▶
3:17 BRCA-P Is a Groundbreaking Breast Cancer Clinical Trial
A video looks at the first clinical trial "to prevent breast cancer in women with a BRCA1 gene mutation."
▶
1:01 What EMERALD Phase III Trial Could Mean for Breast Cancer Patients
Virginia Kaklamani, MD, breast cancer program leader at UT Health San Antonio MD Anderson, presents phase III EMERALD results for oral elacestrant in ER+/HER2- metastatic breast cancer.
▶
2:35 Breast Cancer Trials Clinical Fellowship Program - Dr Julia Dixon-Douglas
Dr Julia Dixon-Douglas on UNRAVEL-TNBC, her Breast Cancer Trials fellowship project into what drives response and resistance to immunotherapy in early-stage triple negative breast cancer.
▶
3:17 The AllClear Project - Breast Cancer Trials
Breast Cancer Trials on AllClear, a five-year program led by Associate Professor Christine Chaffer under a $25 million National Breast Cancer Foundation grant, targeting deaths from recurrent breast cancer.
▶
2:33 The ROSALIE Clinical Trial - Breast Cancer Trials
The ROSALIE trial is testing whether patients can safely skip radiotherapy when no cancer remains in the breast after chemotherapy and surgery.
▶
2:13 Breast Cancer Trials Clinical Fellowship Program - Dr Caroline MacCallum
Dr Caroline MacCallum on her Breast Cancer Trials fellowship project comparing contrast-enhanced mammography with MRI for assessing screen-detected early breast cancer and DCIS.
▶
8:31 Advancing HER2+ Breast Cancer Treatment: Inside the DTP Clinical Trial
Dr. Polly Niravath, Associate Professor and Breast Oncologist, provides an in-depth look at the DTP Clinical Trial and its role in advancing treatments for HER2+ breast cancer.
▶
2:29 The PROSPECTIVE Clinical Trial - Monica Kelly
Monica Kelly is a participant in the PROSPECTIVE trial, which is testing whether surgery without radiotherapy still stops breast cancer coming back.
▶
1:57 The OPTIMA Clinical Trial
Dr Belinda Kiely, Study Chair of the OPTIMA clinical trial, explains the purpose of the study and who is eligible to take part, for Breast Cancer Trials.
▶
2:25 The FINER Clinical Trial for Breast Cancer
Professor Andrew Redfern, Study Chair of the Breast Cancer Trials FINER clinical trial, discusses the clinical trial of Ipatasertib and how it may benefit patients.